Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2010

View Archived Issues

ENB-0040 shows promise to treat hypophosphatasia in children

Serodus identifies new serotonin 5-HT4 receptor antagonists

AMG-386 is active in renal cell carcinoma and ovarian cancer

Panobinostat has antitumor activity in phase II trial in SCLC

Adjuvanted VZV subunit vaccine gE/AS01B is more immunogenic than Varilrix

CMX-001 effective in immunocompromised adenovirus-infected patients

Pradaxa arrives in U.S. pharmacies

Primary endpoint met in phase III HPN-100 trial in urea cycle disorders

Incyte begins global phase III INCB-18424 trial in polycythemia vera

Shire presents new prodrugs of opioids for the treatment of pain

Phase III data reported on linaclotide in IBS with constipation

New ligands of glucocorticoid receptors disclosed by AstraZeneca

RegeneRx Biopharma reports preclinical data on RGN-259 for dry eye syndrome

New metabotropic glutamate mGlu2 receptor agonists claimed

CeNeRx BioPharma presents safety data on new CX-157 formulation

Medicago's H5N1 avian flu vaccine approved to enter phase II trial

New beta-secretase 1 inhibitors patented

FDA approves Teflaro for CABP and ABSSSI in adults

Soligenix presents preliminary phase Ib safety data on RiVax

BC-819 shows good safety profile in phase I/IIa trial in pancreatic cancer

MabThera approved in E.U. as maintenance treatment of follicular lymphoma

Viralytics submits IND for phase II trial of Cavatak in melanoma

Phase II CD-NP trial in acute decompensated heart failure meets endpoint

Gynecologic Oncology Group to begin phase II elesclomol trial in ovarian cancer

FDA extends review of BMS' BLA for ipilimumab in advanced melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.